1487 results about "Ester derivatives" patented technology

A pharmaceutical composition in unit dose form, comprising an essentially homogeneous solution comprising a statin essentially dissolved in solvent system comprising natural or synthetic omega-3 fatty acids or pharmaceutically acceptable esters, derivatives, conjugates, precursors or salts thereof, or mixtures thereof, wherein less than 10% of the statin is undissolved in the solvent system.

PCT No. PCT / EP97 / 04908 Sec. 371 Date Mar. 17, 1999 Sec. 102(e) Date Mar. 17, 1999 PCT Filed Sep. 19, 1997 PCT Pub. No. WO98 / 12242 PCT Pub. Date Mar. 20, 1998Biodegradable polyesters based on A) 95-99.99 mol % of at least one polyester A containing as monomeric building blocks of an acid component comprising a11) 20-95 mol % of at least one aliphatic or cycloaliphatic dicarboxylic acid or its ester-forming derivative and a12) 5-80 mol % of at least one aromatic dicarboxylic acid or its ester-forming derivative and at least one dihydroxy compound or at least one amino alcohol or their mixtures, and B) 0.01-5 mol % of a mixture comprising mono-, bi-, tri-, tetra- and higher-nuclear isocyanurates or corresponding compounds containing two, three or four functional groups capable of reacting with the end groups of polyester A, or mixtures of the isocyanurates and the corresponding compounds, as well as molding compositions comprising said polyesters, their manufacture and their use in the manufacture of moldings, filsm, fibers and coatings.

The present invention relates to a hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid or an ester derivative thereof as effective ingredients. According to the present invention, a type IIb and type IV hyperlipemia therapeutic agent having an excellent effect of lowering the cholesterol and triglyceride in blood is provided.

The present invention provides a surfactant making it possible to obtain particles comprising a fluoropolymer at a size smaller in diameter in an aqueous dispersion obtained by polymerization in the presence of the same. The present invention is a surfactant comprising a fluorine-containing-sulfobutanedioic-acid-ester derivative represented by the general formula (i): Y—Rf1—(CH2)m—OCOCH(SO3M)-CH2COO—(CH2)n—Rf2—Y  (i) wherein Y represents hydrogen atom or fluorine atom; when Y is hydrogen atom, one of Rf1 and Rf2 is —(CF2CF2)3— and the other is —(CF2CF2)2— or —(CF2CF2)3— and, when Y is fluorine atom, Rf1 and Rf2 are the same or different and each is a divalent hydrocarbon group containing 1 to 4 carbon atoms and containing at least one fluorine atom; m and n are the same or different and each represents an integer of 1 to 3; and M represents NH4, Li, Na, K or H.

The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the biomedical, sanitary and surgical fields, and in the medical field as controlled release systems for drugs.

A non-aqueous secondary battery contains a positive electrode, a negative electrode, a separator and a non-aqueous electrolytic solution. The positive electrode contains a layered structure lithium-containing compound oxide, or a spinel lithium-containing compound oxide containing manganese as an active material. The non-aqueous electrolytic solution contains at least one additive selected from a sulfonic acid anhydride, a sulfonate ester derivative, a cyclic sulfate derivative and a cyclic sulfonate ester derivative, and a vinylene carbonate or a derivative of the vinylene carbonate.

The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions of the present invention contain a compound of following formula (Ia):R—CO-CAP   (Ia)wherein CAP refers to collectively the capsaicins represented in FIG. 1 and a compound of formula (Ib):MCO-O—R   (Ib)wherein MCO refers to myristoleic acid.In formulae Ia and Ib, R is selected from alkyl groups of up to about 18 carbon atoms and aryl groups of up to about 18 carbon atoms and alkylene group of up to about 18 carbon atoms and an arylene group of up to about 18 carbon atoms. The alkyl, aryl and alkylene groups may be substituted or un-substituted, branched or straight chains. In addition, R may contain heteroatoms and may be straight chained or branched.The pharmaceutical compositions containing compounds of formulae Ia and Ib are useful for pain management in mammals in vivo and have been contemplated to be used in the treatment of various pains in humans.

The present invention relates to cooling compositions comprising a cooling agent (preferably menthyl lactate) together with an ester derivative (preferably tri-ethyl citrate). Such compositions deliver immediate and long lasting freshness sensation, while maintaining or even improving skin and / or mucosal membrane health to which they are contacted and deodorizing said skin and / or mucosal membrane.

This invention provides cellulose ester interpolymers, and methods of oxidizing cellulose interpolymers and cellulose ester interpolymers. The invention also provides routes to access carboxylated cellulose ester derivatives with high acid numbers wherein the carboxyl group is attached directly to the cellulose backbone by a carbon-carbon bond. Through functionalization of an intermediate aldehyde, the corresponding cationic or zwitterionic cellulose ester derivatives can also be accessed. The interpolymers of the present invention have a number of end-use applications, for example, as binder resins in various types of coating compositions and as drug delivery agents.

Phosphonate-nucleotide ester compounds of the formula (I) have excellent antiviral activity and antineoplastic activity. Further, they can be orally administered. wherein ring A represents wherein R1 and R2 independently represent hydrogen, halogen, hydroxyl, mercapto, C6-C10 arylthio or amino; R3 represents C1-C4 alkyl or ethyl having one or more substituents selected from the group consisting of fluorine, C1-C4 alkoxy, phenoxy, C7-C10 phenylalkoxy and C2-C5 acyloxy; R4 represents ethyl having one or more substituents selected from the group consisting of fluorine, C1-C4 alkoxy, phenoxy, C7-C10 phenylalkoxy and C2-C5 acyloxy; X, Y and Z independently represent methyne or nitrogen atom; or a pharmaceutically acceptable salt thereof.

The present process provides an improved method for converting 2′-deoxy-2′-fluoro-2′-methyl-D-ribonolactones derivatives to 3-fluoro-3-methyl-2-chlorofuran compounds which are useful for the synthesis of nucleosides and improved processes for the synthesis of the D-ribonolactone compounds.

The invention relates to dabigatran ester derivatives as shown in a constitutional formula I, pharmaceutically acceptable nontoxic salts thereof, medical composite containing the compounds as active components, and application of thrombin inhibitor of the compounds and medical composites, wherein R1 represents H or C1 to C5 alkyl; R2 represents H, or C1 to C3 alkyl; and R3 represents C1 to C8 alkyl or substituted alkyl.

The present invention provides a salicylic acid ester derivative having an impurity content lower than a specific level and expressed by the following formula (1)(in the formula, R1 is methyl group or ethyl group, R2, which may be substituted optionally, is an alkyl group having a carbon number of from 1 to 30, alkoxy group having a carbon number of from 1 to 30, aryl group having a carbon number of from 6 to 30, aryloxy group having a carbon number of from 6 to 30, aralkyl group having a carbon number of from 6 to 30 or aralkyloxy group having a carbon number of from 6 to 30). The salicylic acid ester derivative is effective as a terminal blocking agent or a polymerization. promoting agent for a polycarbonate, and gives a polycarbonate having good color tone and suitable for optical material use.

Method and apparatus for coating fertilizer in pellet or other form to impart time-release characteristics and the resulting coated pellet product. The polyurethane coating encapsulates fertilizer particles, forming a hydrophobic coating for slow-release qualities. The urethane polymer coating is formulated with an isocyanate and a combined fluid of a polyether polyol, a methyl ester derivative of plant or vegetable oil, a T-12 curing catalyst, barium sulfate, and an oil-based dye. The barium sulfate imparts physical strength to and enhances color quality of the polyurethane coating, and acts as a detackifier and maintains temperature in the coating reactor. The inventive formulation is effective in the practical polymer coating of sulfate-based or other fertilizer pellets in an inventive time-release fertilizer product. An apparatus is provided for carrying out the coating process.

The present invention provides a catalyst for polyester production capable of producing a polyester with high catalytic activity, a process for producing a polyester using the catalyst and a polyester produced thereby. The catalyst comprises a solid titanium compound obtained by dehydro-drying a hydrolyzate obtained by hydrolysis of a titanium halide and which has a molar ratio (OH / Ti) of a hydroxyl group (OH) to titanium (Ti) exceeding 0.09 and less than 4. In the process, the polyester is obtained by polycondensing an aromatic dicarboxylic acid, or an ester-forming derivative thereof, and an aliphatic diol, or ester-forming derivative thereof, in the presence of the catalyst. The resulting polyester has excellent transparency and tint, a titanium content of 1 to 100 ppm, a magnesium content of 1 to 200 ppm and a magnesium to titanium weight ratio of not less than 0.01.

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to 1 cyclic boronic acid ester derivatives and their use as therapeutic agents.

Disclosed herein is an injectable long-acting analgesic composition comprising: (a) a ketorolac ester derivative of formula (I),  wherein  R is a straight-chain or branched saturated or unsaturated C1-C20 aliphatic group optionally substituted with a C6-C10 aryl group; and (b) a pharmaceutically acceptable oil vehicle. The composition can provide a longer duration of action and, therefore, is suitable for use in the treatment of long-lasting pains and inflammations.

The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions of the present invention contain a compound of following formula (Ia):R—CO—CAP  (Ia)wherein CAP refers to collectively the capsaicins represented in FIG. 1 and a compound of formula (Ib):MCO—O—R  (Ib)wherein MCO refers to myristoleic acid.In formulae Ia and Ib, R is selected from alkyl groups of up to about 18 carbon atoms and aryl groups of up to about 18 carbon atoms and alkylene group of up to about 18 carbon atoms and an arylene group of up to about 18 carbon atoms. The alkyl, aryl and alkylene groups may be substituted or un-substituted, branched or straight chains. In addition, R may contain heteroatoms and may be straight chained or branched.The pharmaceutical compositions containing compounds of formulae Ia and Ib are useful for pain management in mammals in vivo and have been contemplated to be used in the treatment of various pains in humans.

Oral care compositions having improved taste, said compositions comprising: a carrier material; from about 0.001 to about 10%, by weight of the composition, of an oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants, or a combination thereof; and from about 0.0001 to about 1%, by weight of the composition, of a TRPA1 agonist selected from vanillin esters; benzoate esters; hydroxybenzoate derivatives; methoxy benzoate derivatives; hydroxybutanedioate derivatives; benzamidobenzoate derivatives; methylpropanoate derivatives; phenyl acetate derivatives; hex-3-enoate derivatives; 2-(furan-2-ylmethylsulfanyl)-3-methylpyrazine; phenylmethoxymethylbenzene; (2R)-2-azaniumyl-3-[(2R)-2-azaniumyl-3-oxido-3-oxopropyl]disulfanylpropanoate; (3E)-2-hydroxy-4,8-dimethylnona-3,7-dienal; (2R)-2-azaniumyl-3-[(2S)-2-azaniumyl-3-oxido-3-oxopropyl]disulfanylpropanoate; (3Z)-3-butylidene-2-benzofuran-1-one; 3-methyl-N-(3-methylbutyl)butan-1-imine; 2-(furan-2-ylmethyldisulfanylmethyl)furan; and combinations thereof. Uses thereof and methods of improving the taste of an oral care composition.

Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

A non-aqueous electrolyte secondary battery is composed of a positive electrode containing a positive electrode active material capable of storing and releasing lithium ion, a negative electrode containing a negative electrode active material capable of storing and releasing lithium ion, and a non-aqueous electrolyte. The negative electrode active material contains a first material of a graphite material and a second material of a complex in which graphite material and silicon or silicon composite are coated with amorphous carbon material, and a cyclic carbonic acid ester derivative having fluoride atom and a sulfur-containing composite having cyclic structure are added to the non-aqueous electrolyte.

The invention provides moisture-absorbing and flame-retardant copolyester, which comprises terephthalic acid (PTA), other aromatic dicarboxylic acid or ester derivatives, aliphatic diol containing C2 to C6 atoms, a phosphorus flame retardant, moisture-adsorption group containing monomers, copolymer which is polymerized by flexible-chain monomers and contains ether bonds, a heat stabilizer and an anti-oxidation and uvioresistant additive. The textile fabric, which is prepared by spinning the synthesized moisture-absorbing and flame-retardant copolyester, has favorable moisture-absorbing and flame-retardant functions, and greatly improves the wearing comfort and safety flame retardancy of the polyester fabric.

This invention provides cellulose ester interpolymers, and methods of oxidizing cellulose interpolymers and cellulose ester interpolymers. The invention also provides routes to access carboxylated cellulose ester derivatives with high acid numbers wherein the carboxyl group is attached directly to the cellulose backbone by a carbon-carbon bond. Through functionalization of an intermediate aldehyde, the corresponding cationic or zwitterionic cellulose ester derivatives can also be accessed. The interpolymers of the present invention have a number of end-use applications, for example, as binder resins in various types of coating compositions and as drug delivery agents.

The disclosure describes methods of synthesis of phosphonate ester derivatives. Preferred methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of phosphonate ester derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of phosphonate ester derivatives.

The invention relates to a silibinin monoester derivative and its medicine salt or solvates. The invention also relates to its preparation method and its drug combination and medical application. The compound can inhibit activity of hepatitis b virus, so it is expected to be used as drug to treat hepatitis b virus and relevant virus diseases. The compound can protect liver and is expected to be used as drug preventing liver damage. The compound possesses effect anti free radical and is expected to be used as drug treating diseases caused by free radical.